Gain Therapeutics, Inc. (GANX)
Last updated: 2026-11-19 09:23:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Gain Therapeutics, Inc. (GANX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.11, with a market capitalization of $52.54M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.94 to $4.34. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$52.54M | |
$1.11 | |
$1.11 | |
$1.11 | |
$1.11 | |
282.00 | |
547.06K | |
-- | |
$4.34 | |
$0.94 | |
-- | |
2026-09-30 |
Gain Therapeutics, Inc. (GANX) Pre-Market Stock Price
Gain Therapeutics, Inc. (GANX) is trading at $1.11 in pre-market trading as of 2026-11-19 09:14:00, unchanged from the previous close of $1.11
Pre-market trading shows how investors are pricing GANX before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Gain Therapeutics, Inc. (GANX) 7-Day Stock Price Change
Over the past seven days, Gain Therapeutics, Inc. (GANX) moved from $1.08 to $1.11, representing a gain of 2.78% ($0.03).
The stock traded between $0.94 and $1.30 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1.06 million shares, up versus the previous seven-day period, indicating higher trading activity.
GANX 52-Week Price Position
Position in Range: 5.0%
GANX is currently trading at $1.11, placing it 5.0% of the way from its 52-week low of $0.94 to its 52-week high of $4.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Gain Therapeutics, Inc. (GANX)?
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Gain Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
GANX News
Latest news related to Gain Therapeutics, Inc. and GANX stock.
- Read Full Article
- Read Full Article
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q3 earnings
Ways to Trade GANX at MEXC
How to Buy Gain Therapeutics, Inc. (GANX) Stock on MEXC
Eligible investors can buy real shares of Gain Therapeutics, Inc. (GANX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Gain Therapeutics, Inc. (GANX) stock price today?
2.Is GANX stock going up or down today?
3.What is GANX pre-market price?
4.What is GANX after-hours price?
5.Is GANX stock trading now?
6.Where does GANX sit relative to its 52-week high and low?
7.What sector is Gain Therapeutics, Inc. in?
8.What is Gain Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is GANX valued in terms of P/E ratio and EPS?
10.Does Gain Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GANX, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
GANX Stock Calculator
Estimate the value between GANX shares and USD.
GANX Shares to USD
1.00 GANX shares = 1.11 USD
Calculations are estimates based on the latest available price and are for reference only.


